FO
BIIB icon

FT Options’s Biogen BIIB Stock Holding History

FT Options’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,191
Closed -$905K – 293
2016
Q4 		$905K Buy
+3,191
New +$946K 1.04% 25
2016
Q3 		– Sell
-14,632
Closed -$4.33M – 379
2016
Q2 		$3.54M Buy
14,632
+13,516
+1,211% +$3.56M 3.04% 6
2016
Q1 		$291K Sell
1,116
-4,100
-79% -$1.08M 0.3% 65
2015
Q4 		$1.6M Buy
+5,216
New +$1.5M 1.18% 25

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FT Options's BIIB Position: Q1 2017 in Review

FT Options sold out of Biogen (BIIB) in Q1 2017, closing a stake of 3,191 shares — an estimated $905K sold.

FT Options first reported a position in BIIB in Q4 2015 and held it in 4 quarters. The position peaked at $3.54M in Q2 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • FT Options reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • FT Options sold 3,191 Biogen shares in Q1 2017, an estimated $905K.
  • FT Options first reported a position in Biogen in Q4 2015 and held it in 4 quarters.
  • FT Options's Biogen position peaked at $3.54M in Q2 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.